To select a GW873140 dose and dosage regimen for further evaluation based on comparison of the short-term antiviral activity, safety and tolerability of different oral doses of GW873140 in combination with LPV/r in HIV-1 infected therapy-naive subjects.

Be treatment-naive, defined as less than or equal to 2 weeks of treatment with a protease inhibitor (PI) or an nucleoside reverse transcriptase inhibitor/nucleotide reverse transcriptase inhibitor (NRTI/ NtRTI), or less than or equal to 7 days of therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI).

Prior treatment with any entry inhibitor, attachment inhibitor, or fusion inhibitor (experimental or approved) is not allowed.

Be able to understand and follow with protocol requirements, instructions and protocol-stated restrictions.

Signed and dated written informed consent prior to study entry.

Exclusion criteria:

No detection of CXC Receptor4-tropic (X4-tropic) virus only, based on viral tropism test at screening.

No active Class C AIDS-defining illness.

No laboratory abnormalities at screen.

No significant blood loss prior to study start.

No pregnant or breastfeeding women.

Additional qualifying criteria to be determined by the physician.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00102778